Answers are grounded in this paper and cite their sources.
Prostate-specific membrane antigen (PSMA) is an ideal target of prostate cancer (PCa) for theranostics, combining diagnosis and therapy in the field of nuclear medicine. [ 177 Lu]Lu-PSMA-617 is a gold standard in PSMA-targeting radioligands, whereas its rapid clearance from the tumor and high uptake in the kidney may compromise the efficacy of theranostics. In this study, we developed novel PSMA-targeting radioligands, [ 111 In]In/[ 225 Ac]Ac-PDI2 and [ 111 In]In/[ 225 Ac]Ac-PDI4, by introducing a positively charged diethylenetriamine (PEI2) or tetraethylenepentamine (PEI4) structure, respectively, to PSMA-617. In the biodistribution study, higher tumor retention and lower renal uptake of [ 111 In]In-PDI2 and [ 111 In]In-PDI4 were observed than those of [ 111 In]In-PSMA-617, and [ 111 In]In-PDI2 exhibited higher tumor-residualizing properties than [ 111 In]In-PDI4. [ 111 In]In-PDI2 and [ 111 In]In-PDI4 clearly visualized PSMA-expressing tumors by single photon emission computed tomography/computed tomography (SPECT/CT). The administration of [ 225 Ac]Ac-PDI2 led to a higher antitumor effect than [ 225 Ac]Ac-PDI4 and [ 225 Ac]Ac-PSMA-617. These findings suggest the utility of [ 111 In]In/[ 225 Ac]Ac-PDI2 as theranostic ligands for PCa.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: